About Genfit
Genfit is a company based in Loos (France) founded in 1999. The company has 180 employees. Genfit has completed 1 acquisition, including Versantis. Genfit operates in a competitive market with competitors including NGM Biopharmaceuticals, MannKind Corp, Rhythm Pharmaceuticals, Corcept and ViaCyte, among others.
- Headquarter Loos, France
- Employees 180
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website genfit.com
- Social LinkedIn
- Legal Name Genfit Sa
Funding Insights of Genfit
- Total Rounds 8
- Last Round Post-IPO — $213.02M
- Investors Count 1
All 8 funding rounds of Genfit with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2017 | $213.02M | Post-IPO | – | – | – |
| Oct 2016 | $38.01M | Post-IPO | – | – | – |
| Feb 2016 | $54.2M | Post-IPO | – | – | – |
| Dec 2014 | $25.93M | Post-IPO | – | – | – |
| Jun 2014 | $67.58M | Post-IPO | – | – | – |
| Apr 2013 | $18.77M | Post-IPO | – | – | – |
| Jul 2011 | $7.25M | Post-IPO | – | – | – |
| Jun 1999 | – | Private Equity Round | – | – |
1 investors in total: 1 institutional.
Investors in Genfit
Genfit has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Finorpa.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | finorpa.fr | - |
Investor details for Genfit
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Genfit
55 people are tracked at Genfit (18 in leadership, 13 in board & advisors, 24 in team); the tracked headcount is 180.
| Name | Role | Group |
|---|---|---|
Pascal Caisey | Chief Operating Officer | Leadership |
Carol Addy | Chief Medical Officer | Leadership |
Jean-Christophe Marcoux | Chief Corporate Affairs Officer | Leadership |
Pascal Prigent | CEO | Leadership |
Laurent Lannoo | Corporate Secretary & Director of Legal Affairs | Leadership |
Dean Hum | Chief Scientific Officer | Leadership |
Thomas Baetz | Chief Financial Officer | Leadership |
Nathalie Doize | Sr VP Clinical Operations | Leadership |
Caisey Pascal | Deputy CEO / Chief Operating Officer | Leadership |
Rania Harisseh | Director Clinical Research | Leadership |
Nathalie Mboro | Head Of Internal Audit | Leadership |
Marie-Jeanne Joissains | CMC Director | Leadership |
Zouher Majd | Director Of Scientific Operations | Leadership |
Katharina Staufer | Senior Vice President Clinical Strategy | Leadership |
Anila Mico | Senior Vice President Regulatory Affairs | Leadership |
Stephane Thomas | Vice President Biometry | Leadership |
Jeremy Magnanensi | Director - Biostatistical Projects R&d | Leadership |
Stéphanie Petit | Clinical Operations Director | Leadership |
Jean-François Mouney | Chair | Board & advisors |
Scott Friedman | Scientific Advisor | Board & advisors |
35 more people are available in the full profile.
Complete people profiles for Genfit
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Genfit
Genfit is a publicly listed company on the EURONEXT with ticker symbol GNFT in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Mar 2019
- Listed onNASDAQ: GNFT
- Listed entityGenfit SA
- Exchange sectorHealth technology
- ISINFR0004163111
- Share price8.28 EUR (-0.6% on the day) · 2026-10-09
- Market capitalisation415,654,680.00 EUR
- EPS (diluted, trailing year)-2.05 EUR
- Volume (last session)376,719
Financials of Genfit
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 65.4M EUR | -86.0M EUR | -8.0M EUR |
| 2024 | 67.0M EUR | 1.5M EUR | 1.4M EUR |
| 2023 | 28.6M EUR | -28.9M EUR | -34.9M EUR |
| 2022 | 20.2M EUR | -23.7M EUR | -31.2M EUR |
| 2021 | 80.1M EUR | 67.3M EUR | 29.9M EUR |
Detailed financial statements for Genfit
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genfit
Genfit has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Versantis.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Treatments for orphan and rare pediatric liver disorders are developed. | versantis.com | Zurich, Switzerland | 2015 | Sep 2022 | $109M |
Complete acquisition details for Genfit
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Genfit
5 dated milestones of Genfit across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Genfit is founded.
- Funding First funding round.
- Funding Latest funding round, Post-IPO, of $213.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Versantis.
Competitors of Genfit
Genfit operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, MannKind Corp, Rhythm Pharmaceuticals, Corcept and ViaCyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. | |
| mannkindcorp.com | 1991 | Los Angeles, United States | $50M | 322 | Developer of small-molecule drugs | |
| rhythmtx.com | 2010 | Boston, United States | $84M | 115 | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | |
| corcept.com | 1998 | Menlo Park, United States | – | 352 | Developer of cortisol modulators for the treatment of various diseases | |
| viacyte.com | 1999 | San Diego, United States | $389.03M | 126 | Cell therapy for diabetes is developed from stem cells. | |
| 89bio.com | 2018 | San Francisco, United States | $60M | 70 | Developer of therapies for treating nonalcoholic steatohepatitis and other liver and metabolic disorders | |
| metacrine.com | 2015 | San Diego, United States | $124.77M | 32 | Developer of protein sensitizers for insulin in type 2 diabetes and modulators for metabolic diseases | |
| alnara.com | 2008 | Cambridge, United States | $55M | – | Protein therapeutics for metabolic diseases are developed orally. | |
| enobia.com | 1997 | Quebec, Canada | $138.52M | – | Therapies for genetic metabolic bone disorders are developed. |
Detailed competitors of Genfit
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Genfit
The website of Genfit (genfit.com) receives about 4.9K visits a month and ranks #3,666,893 among all websites worldwide, #4,704 in Biotechnology and Pharmaceuticals.
- Monthly visits4.9K
▲ 6% vs previous month
- Unique visitors1.9K
per month
- Global rank#3,666,893
among all websites
- Category rank#4,704
Health · Biotechnology and Pharmaceuticals
- Bounce rate36%
- Pages per visit2.2
- Average visit1 min 01 sec
- DevicesDesktop 34% · Mobile 66%
Websites whose visitors overlap most with Genfit. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
gemacbio.com | gemacbio.com | 100% | – | – | – |
| xoma.com | 100% | 8K | #3,718,828 | View details | |
| zymogenetics.com | 100% | – | – | View details | |
| xencor.com | 100% | 22.2K | #2,563,685 | View details | |
| optimerpharma.com | 100% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 15 similar websites and full traffic analytics for Genfit
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 15 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Genfit
Complete news archive for Genfit
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Genfit
10 companies that operate in the same segment as Genfit (Metabolic Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Developer of cortisol modulators for the treatment of various diseases | 1998 | Menlo Park, California, United States | – | USD 761.41 M | 500 | |
Developer of therapies for the treatment of endocrine-related diseases and cancers | 2008 | San Diego, California, United States | USD 103.5 M | USD 1.04 M | 437 | |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | 2009 | Cambridge, Massachusetts, United States | USD 685 M | – | 81 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Solutions for biomarker discovery and diagnostic testing are provided. | 2000 | Morrisville, United States | USD 165.87 M | – | – | |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | 2007 | Fremont, California, United States | USD 61.1 M | USD 407.32 M | 395 | |
Biologics are developed for cardio-metabolic and liver diseases. | 2007 | San Francisco, California, United States | USD 358.87 M | USD 330.53 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Genfit
Genfit was founded in 1999.
Genfit is headquartered in Loos, France. It is registered at Loos, Nord, France.
Genfit has 180 employees.
Annual revenue of Genfit is $76.88M as on Dec 31, 2025.
Genfit engages in the research and development of therapeutics for cardiometabolic and neurodegenerative diseases. Its flagship product Elafibranor is targeted at nonalcoholic steatohepatitis, where it prevents fibrosis production. It is currently in phase 3 clinical trials. The company is also investigating therapeutic interventions in auto-immune, metabolic, inflammatory (chronic inflammatory bowel disease), fibrotic diseases. In addition, Genfit is co-developing therapeutics for mitochondrial dysfunction in type 2 diabetes and kidney disease, in collaboration with Sanofi.
Genfit's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Corcept.
Yes, Genfit is publicly traded on EURONEXT under the ticker symbol GNFT.
Genfit has made 1 acquisition, including Versantis.
Genfit has 1 investor. Key investors include Finorpa.